Skip to main content
Fig. 2 | BMC Primary Care

Fig. 2

From: Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Fig. 2

Proportion of patients receiving SABA prescriptions in the 12 months before the study visit. Patients were categorized according to investigator-classified asthma severity and practice type. A All patients, B Mild asthma, C Moderate-to-severe asthma. *Patients without SABA prescriptions did not report what reliever they were using. SABA, Short-acting β2-agonist

Back to article page

BMC Primary Care

ISSN: 2731-4553

Contact us